Investor Home

Corporate Profile

BeiGene is a commercial-stage biopharmaceutical company rooted in China that is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

We have three internally-developed late-stage clinical drug candidates:

  • Zanubrutinib (BGB-3111) — an investig...more >
Stock Quotemore >
BGNE (American Depositary Shares)

$169.23

 5.12 (3.12%)

07/20/18  4:00 p.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BeiGene Attends Hearing Before the Listing Committee of the Stock Exchange of Hong Kong Limited - July 20, 2018
CAMBRIDGE, Mass. and BEIJING, China, July 20, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage... Read More
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 3, 2018
CAMBRIDGE, Mass., and BEIJING, China, July 03, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stag... Read More

Upcoming Events

There are currently no events scheduled.

E-mail Alerts

Sign up to receive e-mail alerts